• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Cytosorbents Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    6/13/25 5:15:45 PM ET
    $CTSO
    Medical/Dental Instruments
    Health Care
    Get the next $CTSO alert in real time by email
    false 0001175151 0001175151 2025-06-12 2025-06-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): June 12, 2025

     

    CYTOSORBENTS CORPORATION

     

    (Exact name of registrant as specified in its charter) 

     

    Delaware 001-36792 98-0373793
    (State or other jurisdiction
    of incorporation)
    (Commission
    File Number)
    (IRS Employer
    Identification No.)

     

    305 College Road East, Princeton, New Jersey

    08540
    (Address of principal executive offices) (Zip Code)

     

    Registrant’s telephone number, including area code:(732) 329-8885

     

     
    (Former name or former address, if changed since last report.)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

      ¨  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

      ¨  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

      ¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

      ¨  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class Trading Symbol(s) Name of each exchange on which registered
    Common stock, par value $0.001 per share CTSO The Nasdaq Stock Market LLC (Nasdaq Capital Market)

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

     

     

     

     

     

    Item 5.07Submission of Matters to a Vote of Security Holders

     

    CytoSorbents Corporation (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”) on June 12, 2025. At the Annual Meeting, the following matters were submitted to a vote of stockholders:

     

    1.The election of five (5) directors to serve until the Company’s 2026 Annual Meeting of Stockholders, or until their respective successors are elected, except in the case of the death, resignation or removal of any director;

     

    2.The approval of, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, disclosed pursuant to Item 402 of Regulation S-K; and

     

    3.The ratification of the appointment of WithumSmith+Brown, PC, as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.

     

    At the close of business on April 17, 2025, the record date for the determination of stockholders entitled to vote at the Annual Meeting, there were 62,610,376 shares of the Company’s Common Stock outstanding and entitled to vote at the Annual Meeting. The holders of 40,071,481 shares of the Company’s Common Stock were represented in person or by proxy at the Annual Meeting, constituting a quorum.

     

    At the Annual Meeting, (i) the five (5) directors were elected, (ii) the compensation of the Company’s named executive officers, disclosed pursuant to Item 402 of Regulation S-K, was approved, on a non-binding, advisory basis, and (iii) the appointment of the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025 was ratified.

     

    Proposal No. 1— Election of Directors

     

    The vote with respect to the election of directors was as follows:

     

    Nominees  For   Against   Abstain   Broker Non-Votes 
    Dr. Phillip P. Chan   21,479,032    1,107,546    64,976    17,419,927 
    Dr. Edward R. Jones   19,790,544    2,791,100    69,910    17,419,927 
    Michael Bator   19,687,559    2,705,796    258,199    17,419,927 
    Alan D. Sobel   19,313,170    3,319,370    19,014    17,419,927 
    Jiny Kim   21,388,189    913,647    349,718    17,419,927 

     

    Proposal No. 2 — Approval of the Compensation of the Company’s Named Executive Officers

     

    The vote with respect to the approval of, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, disclosed pursuant to Item 402 of Regulation S-K was as follows:

     

    For   Against  

    Abstain

       Broker Non-Votes 
     18,189,951    1,720,512    2,741,091    17,419,927 

     

    Proposal No. 3 — Ratification of the Appointment of Independent Registered Public Accounting Firm

     

    The vote with respect to the ratification of the appointment of WithumSmith+Brown, PC, as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025 was as follows:

     

    For   Against   Abstain 
     39,485,868    553,680    31,933 

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    June 13, 2025 CytoSorbents Corporation
       
       
      By: /s/ Dr. Phillip P. Chan
        Name: Dr. Phillip P. Chan
        Title: Chief Executive Officer

     

     

     

    Get the next $CTSO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CTSO

    DatePrice TargetRatingAnalyst
    9/7/2023$4.00Buy
    B. Riley Securities
    10/14/2021$10.00Buy
    B. Riley Securities
    More analyst ratings

    $CTSO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Mariani Peter J bought $19,294 worth of shares (20,000 units at $0.96), increasing direct ownership by 5% to 401,363 units (SEC Form 4)

      4 - Cytosorbents Corp (0001175151) (Issuer)

      12/16/24 7:00:11 AM ET
      $CTSO
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Mariani Peter J bought $27,975 worth of shares (31,363 units at $0.89), increasing direct ownership by 9% to 381,363 units (SEC Form 4)

      4 - Cytosorbents Corp (0001175151) (Issuer)

      12/13/24 8:00:13 AM ET
      $CTSO
      Medical/Dental Instruments
      Health Care
    • Sobel Alan D. bought $30,001 worth of shares (22,557 units at $1.33), increasing direct ownership by 28% to 101,857 units (SEC Form 4)

      4 - Cytosorbents Corp (0001175151) (Issuer)

      12/15/23 4:35:14 PM ET
      $CTSO
      Medical/Dental Instruments
      Health Care

    $CTSO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • B. Riley Securities initiated coverage on CytoSorbents with a new price target

      B. Riley Securities initiated coverage of CytoSorbents with a rating of Buy and set a new price target of $4.00

      9/7/23 8:13:32 AM ET
      $CTSO
      Medical/Dental Instruments
      Health Care
    • B. Riley Securities resumed coverage on CytoSorbents with a new price target

      B. Riley Securities resumed coverage of CytoSorbents with a rating of Buy and set a new price target of $10.00

      10/14/21 7:58:45 AM ET
      $CTSO
      Medical/Dental Instruments
      Health Care

    $CTSO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CytoSorbents Provides U.S. FDA and Health Canada Regulatory Update for DrugSorb-ATR

      PRINCETON, N.J., July 2, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in blood purification therapies for life-threatening conditions in the intensive care unit and cardiac surgery, today provided a regulatory update on its marketing applications for DrugSorb™-ATR with the U.S. Food and Drug Administration (FDA) and Health Canada.  DrugSorb-ATR is an FDA-designated Breakthrough Device designed to reduce the severity of bleeding in patients undergoing coronary artery bypass grafting (CABG) surgery within 2 days of stopping the antiplatelet drug Brilinta® (ticagrelor, AstraZeneca), a commonly used blood thinner.

      7/2/25 7:00:00 AM ET
      $CTSO
      Medical/Dental Instruments
      Health Care
    • CytoSorbents Files Appeal with U.S. FDA for Supervisory Review of its De Novo Request for DrugSorb™-ATR

      PRINCETON, N.J., June 24, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that on June 18, 2025, it filed a request for supervisory review (administrative appeal) with the U.S. Food and Drug Administration (FDA) under 21 CFR 10.75, of the De Novo Denial Letter issued on April 25, 2025 for CytoSorbents' DrugSorb-ATR Device,  (the denial letter).  DrugSorb-ATR, which previously received Breakthrough Device Designation from the FDA, is designed to reduce the severity of bleeding in patients undergoing coronary artery bypass grafting (CABG

      6/24/25 7:00:00 AM ET
      $CTSO
      Medical/Dental Instruments
      Health Care
    • CytoSorbents to Participate at the Jefferies Global Healthcare Conference

      PRINCETON, N.J., May 29, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that management will present and participate in one-on-one meetings with investors at the Jefferies Global Healthcare Conference in New York, NY on June 4 – 5, 2025. CTSO) is a leader in the treatment of life-threatening conditions using blood purification. CytoSorbents' flagship product, CytoSorb®, is approved in the European Union and distributed in over 70 countries worldwide. CytoSorbents is

      5/29/25 7:00:00 AM ET
      $CTSO
      Medical/Dental Instruments
      Health Care

    $CTSO
    SEC Filings

    See more
    • Cytosorbents Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Cytosorbents Corp (0001175151) (Filer)

      7/2/25 4:06:38 PM ET
      $CTSO
      Medical/Dental Instruments
      Health Care
    • Cytosorbents Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Cytosorbents Corp (0001175151) (Filer)

      6/24/25 4:06:16 PM ET
      $CTSO
      Medical/Dental Instruments
      Health Care
    • Cytosorbents Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Cytosorbents Corp (0001175151) (Filer)

      6/13/25 5:15:45 PM ET
      $CTSO
      Medical/Dental Instruments
      Health Care

    $CTSO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bator Michael G. increased direct ownership by 7% to 151,273 units (SEC Form 4)

      4 - Cytosorbents Corp (0001175151) (Issuer)

      3/4/25 9:00:21 PM ET
      $CTSO
      Medical/Dental Instruments
      Health Care
    • President and COO Capponi Vincent increased direct ownership by 2% to 677,168 units (SEC Form 4)

      4 - Cytosorbents Corp (0001175151) (Issuer)

      2/26/25 7:29:54 PM ET
      $CTSO
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Mariani Peter J increased direct ownership by 8% to 466,613 units (SEC Form 4)

      4 - Cytosorbents Corp (0001175151) (Issuer)

      2/26/25 7:28:35 PM ET
      $CTSO
      Medical/Dental Instruments
      Health Care

    $CTSO
    Financials

    Live finance-specific insights

    See more
    • CytoSorbents Reports First Quarter 2025 Financial Results and Provides Business Update

      PRINCETON, N.J., May 14, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the first quarter ended March 31, 2025, and recent business highlights.  CTSO) is a leader in the treatment of life-threatening conditions using blood purification. CytoSorbents' flagship product, CytoSorb®, is approved in the European Union and distributed in over 70 countries worldwide. CytoSorbents is conducting trials to support FDA marketing approval of DrugSorb™-ATR for

      5/14/25 4:01:00 PM ET
      $CTSO
      Medical/Dental Instruments
      Health Care
    • CytoSorbents to Report First Quarter 2025 Financial Results and Recent Business Highlights

      PRINCETON, N.J., April 29, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report first quarter 2025 financial results and recent business highlights after the market close on Wednesday, May 14, 2025. CTSO) is a leader in the treatment of life-threatening conditions using blood purification. CytoSorbents' flagship product, CytoSorb®, is approved in the European Union and distributed in over 70 countries worldwide. CytoSorbents is conducting trials to support FDA marketing approv

      4/29/25 7:00:00 AM ET
      $CTSO
      Medical/Dental Instruments
      Health Care
    • CytoSorbents Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

      2024 marked by strong commercial execution and improved operating leverageCompany continues to expect DrugSorb-ATR regulatory decisions from Health Canada and US FDA in 2025 Successful Rights Offering and exercise of Series A Right Warrants strengthens balance sheetStrengthening of clinical portfolio across cardiac surgery and critical care in 2025 with new presentations and publications The Company has now adopted the standard accounting convention of reporting Revenue to only include Product Sales. Grant Income is no longer reported as a component of RevenuePRINCETON, N.J., March 31, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening

      3/31/25 4:15:00 PM ET
      $CTSO
      Medical/Dental Instruments
      Health Care

    $CTSO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Cytosorbents Corporation

      SC 13G/A - Cytosorbents Corp (0001175151) (Subject)

      11/14/24 4:48:32 PM ET
      $CTSO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Cytosorbents Corporation

      SC 13G - Cytosorbents Corp (0001175151) (Subject)

      2/14/24 4:42:32 PM ET
      $CTSO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Cytosorbents Corporation

      SC 13G - Cytosorbents Corp (0001175151) (Subject)

      2/14/24 9:00:04 AM ET
      $CTSO
      Medical/Dental Instruments
      Health Care

    $CTSO
    Leadership Updates

    Live Leadership Updates

    See more
    • CytoSorbents Appoints Melanie Grossman, CPA as Vice President and Corporate Controller

      Ms. Grossman brings 25 years of accomplished finance and accounting experience in global, publicly-traded companies Company announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PRINCETON, N.J., April 17, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced the appointment of Melanie Grossman, CPA as Vice President and Corporate Controller.  Ms. Grossman joins CytoSorbents with over 25 years of accomplished finance and accounting experience in global, publicly-traded companies. 

      4/17/25 7:00:00 AM ET
      $CTSO
      Medical/Dental Instruments
      Health Care
    • CytoSorbents Appoints Thomas Shannon as Vice President of Marketing for North America

      PRINCETON, N.J., April 14, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced the appointment of Thomas Shannon as Vice President of Marketing for North America. With anticipated marketing approval, Mr. Shannon will lead the marketing strategy and execution for DrugSorb™-ATR in the U.S. and Canada. CTSO) is a leader in the treatment of life-threatening conditions using blood purification. CytoSorbents' flagship product, CytoSorb®, is approved in the European Union and di

      4/14/25 7:00:00 AM ET
      $CTSO
      Medical/Dental Instruments
      Health Care
    • CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India

      PRINCETON, N.J. and HYDERABAD, India, Nov. 11, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit (ICU) and during cardiac surgery through blood purification, and Converge Biotech, a prominent healthcare company with a strong critical care and infectious disease focus in India, are pleased to announce a new strategic collaboration where the two companies seek to expand their combined market reach in the sepsis and critical care markets in India with a broad synergistic product portfolio. CytoSorbents is renowned for its flagship product, CytoSorb®, a blood purification technology that red

      11/11/24 7:30:00 AM ET
      $CTSO
      Medical/Dental Instruments
      Health Care